Literature DB >> 12954799

Contractions to histamine in pulmonary and mesenteric arteries from endotoxemic rabbits: modulation by vascular expressions of inducible nitric-oxide synthase and histamine H1-receptors.

Naoyuki Matsuda1, Yuichi Hattori, Xiao-Hong Zhang, Hiroyuki Fukui, Osamu Kemmotsu, Satoshi Gando.   

Abstract

The inducible isoform of nitric-oxide synthase (iNOS) is highly expressed after induction of endotoxemia and contributes to vascular hypocontractility in endotoxemia. Circulating levels of histamine are elevated in animal models of sepsis and in patients with septic shock. This study assessed whether the vascular effects of histamine play a significant role in the pathophysiology of endotoxemic shock despite the hyporesponsiveness to vasoconstrictors associated with iNOS up-regulation. Rabbits were rendered endotoxemic by lipopolysaccharide (LPS; 100 microg/kg, i.v.). In mesenteric arteries taken from animals at 6 h of LPS administration, the contractile response to histamine was significantly impaired but histamine-evoked contractions in pulmonary arteries were unchanged. Western blot revealed a drastic increase in iNOS expression in mesenteric vessels after LPS, but endotoxin-induced iNOS increase was not so marked in pulmonary vessels. On the other hand, expression of endothelial nitric-oxide synthase was suppressed under LPS challenge in both types of vessels. In the presence of NG-nitro-l-arginine or (S)-ethylisothiourea used for iNOS inhibition, histamine-evoked contractions of endotoxemic pulmonary and mesenteric vessels were significantly enhanced. This was possibly associated with a dramatic increase in H1-receptor expression at the gene and protein levels, as determined by Northern blot and immunoblot analyses. Furthermore, we found that LPS-induced endotoxemia caused prominent increases in production of histamine through induction of histidine decarboxylase in tissues, including blood vessels. From these results, we propose that histamine may contribute to the development of endotoxin-induced pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954799     DOI: 10.1124/jpet.103.054163

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Resveratrol Prevented Lipopolysaccharide-Induced Endothelial Dysfunction in Rat Thoracic Aorta Through Increased eNOS Expression.

Authors:  Seda Sultan Uğurel; Nilay Kuşçu; Çiler Çelik Özenci; Selvinaz Dalaklıoğlu; Arda Taşatargil
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

2.  Histamine-mediated increases in cytosolic [Ca2+] involve different mechanisms in human pulmonary artery smooth muscle and endothelial cells.

Authors:  Joseph R H Mauban; Katherine Wilkinson; Christian Schach; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2005-09-14       Impact factor: 4.249

3.  Beneficial effect of the oligomerized polyphenol oligonol on high glucose-induced changes in eNOS phosphorylation and dephosphorylation in endothelial cells.

Authors:  Xiao-Hong Zhang; Hiroki Yokoo; Hiroshi Nishioka; Hajime Fujii; Naoyuki Matsuda; Toshio Hayashi; Yuichi Hattori
Journal:  Br J Pharmacol       Date:  2010-01-29       Impact factor: 8.739

Review 4.  Alert cell strategy in SIRS-induced vasculitis: sepsis and endothelial cells.

Authors:  Naoyuki Matsuda
Journal:  J Intensive Care       Date:  2016-03-23

5.  Differential protection against oxidative stress and nitric oxide overproduction in cardiovascular and pulmonary systems by propofol during endotoxemia.

Authors:  Yen-Chin Liu; Alice Y W Chang; Yu-Chuan Tsai; Julie Y H Chan
Journal:  J Biomed Sci       Date:  2009-01-15       Impact factor: 8.410

6.  Critical role of endogenous histamine in promoting end-organ tissue injury in sepsis.

Authors:  Mizuki Hattori; Mitsuaki Yamazaki; Wakana Ohashi; Satoshi Tanaka; Kohshi Hattori; Kenichiro Todoroki; Toshio Fujimori; Hiroshi Ohtsu; Naoyuki Matsuda; Yuichi Hattori
Journal:  Intensive Care Med Exp       Date:  2016-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.